BioVie reported complete enrollment in its Phase 2 ADDRESS-LC trial of Bezisterim for neurological symptoms of Long COVID. The update is a modest clinical-development milestone and suggests the study is progressing on schedule. The news is positive for the pipeline but is unlikely to materially move the broader market.
BioVie reported complete enrollment in its Phase 2 ADDRESS-LC trial of Bezisterim for neurological symptoms of Long COVID. The update is a modest clinical-development milestone and suggests the study is progressing on schedule. The news is positive for the pipeline but is unlikely to materially move the broader market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
